Therefore, RAS proteins and peptides, and miRNAs and AT1R-AAs that target the RAS, should be measured in placental microvesicles from normal and abnormal placentae as they potentially have a role in dysregulating the maternal RASs, so contributing to the syndrome of preeclampsia. The gene discussed is AGTR1; the disease is preeclampsia.